Strategy overcomes EZH2 inhibitor resistance in SMARCB1-mutated cancer
Inhibitors of the protein EZH2 are effective against cancers with SMARCB1 mutations such as rhabdoid tumors in children. However, these drugs are subject to treatment resistance. Scientists at St. Jude Children's Research ...
May 9, 2022
0
26